COGT   $10.91  3.51% Market Closed After Close 11.088039 1.63%

Cogent Biosciences Inc
Last Events:

2023-08-09 Signal in MACD changed from bearish reversal to bearish. Oscillator MACD is in the negative territory it's lower than the signal line and it crossed the zero line from the top. These factors mean that there is probably a falling trend. Last signal: down-crossing the middle level.

2023-08-09 Trend Power changed from to almost flat.

2023-08-06 Signal in MACD changed from bullish weakening to bearish reversal. Oscillator MACD is in the positive territory it crossed the signal line from the top and falls. These factors mean that the market confirms the end of the upward trend. Last signal: main and signal line crossing.

2023-08-06 Signal in EMA100 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-05 Trend pattern changed from симметричный треугольник to восходящий треугольник.

2023-08-05 Signal in Stochastic changed from bearish reversal to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.

2023-08-05 Signal in RSI changed from bullish weakening to bearish. RSI indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: exit from the overbought zone.

2023-08-05 Signal in EMA50 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.


Current temperature: 7.17
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 10
Target Price Mean 16.20
Mean unverified/preliminary 16.20 / 16.20
Target Price Low / High 10.00 / 22.00
Median / STD DEV 16.50 / 3.99
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Buy
rsi Sell None ActivelyBuy
macd None None None
stoch None None None
ma20 ActivelyBuy Sell Sell
ma50 None None None
ma100 Sell Sell ActivelyBuy
Candlestick PatternSept. 5, 2024 Bearish Advance Block Formation - consists of three white bodies with consecutively higher closes in a uptrend. The last two days have long higher shadows. Considered to be a bullish reversal pattern.
ISIN US19240Q2012
ceo Mr. Andrew R. Robbins M.B.A.
Website https://www.cogentbio.com
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.